These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 31663736)

  • 61. Functional characterization of heat-shock protein 90 from Oryza sativa and crystal structure of its N-terminal domain.
    Raman S; Suguna K
    Acta Crystallogr F Struct Biol Commun; 2015 Jun; 71(Pt 6):688-96. PubMed ID: 26057797
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Novobiocin induces a distinct conformation of Hsp90 and alters Hsp90-cochaperone-client interactions.
    Yun BG; Huang W; Leach N; Hartson SD; Matts RL
    Biochemistry; 2004 Jun; 43(25):8217-29. PubMed ID: 15209518
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer.
    Moser C; Lang SA; Stoeltzing O
    Anticancer Res; 2009 Jun; 29(6):2031-42. PubMed ID: 19528462
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Assays for identification of Hsp90 inhibitors and biochemical methods for discriminating their mechanism of action.
    Matts RL; Manjarrez JR
    Curr Top Med Chem; 2009; 9(15):1462-78. PubMed ID: 19860729
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias.
    Bansal H; Bansal S; Rao M; Foley KP; Sang J; Proia DA; Blackman RK; Ying W; Barsoum J; Baer MR; Kelly K; Swords R; Tomlinson GE; Battiwalla M; Giles FJ; Lee KP; Padmanabhan S
    Blood; 2010 Nov; 116(22):4591-9. PubMed ID: 20651072
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Molecular chaperone Hsp90 is a therapeutic target for noroviruses.
    Vashist S; Urena L; Gonzalez-Hernandez MB; Choi J; de Rougemont A; Rocha-Pereira J; Neyts J; Hwang S; Wobus CE; Goodfellow I
    J Virol; 2015 Jun; 89(12):6352-63. PubMed ID: 25855731
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Impact of Posttranslational Modifications on the Anticancer Activity of Hsp90 Inhibitors.
    Woodford MR; Dunn D; Miller JB; Jamal S; Neckers L; Mollapour M
    Adv Cancer Res; 2016; 129():31-50. PubMed ID: 26916000
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Hsp90: Friends, clients and natural foes.
    Verma S; Goyal S; Jamal S; Singh A; Grover A
    Biochimie; 2016 Aug; 127():227-40. PubMed ID: 27295069
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Geldanamycin and its derivatives as Hsp90 inhibitors.
    Gorska M; Popowska U; Sielicka-Dudzin A; Kuban-Jankowska A; Sawczuk W; Knap N; Cicero G; Wozniak F
    Front Biosci (Landmark Ed); 2012 Jun; 17(6):2269-77. PubMed ID: 22652777
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Targeted cancer therapy through 17-DMAG as an Hsp90 inhibitor: Overview and current state of the art.
    Mellatyar H; Talaei S; Pilehvar-Soltanahmadi Y; Barzegar A; Akbarzadeh A; Shahabi A; Barekati-Mowahed M; Zarghami N
    Biomed Pharmacother; 2018 Jun; 102():608-617. PubMed ID: 29602128
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A novel class of small molecule inhibitors of Hsp90.
    Yi F; Regan L
    ACS Chem Biol; 2008 Oct; 3(10):645-54. PubMed ID: 18785742
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Heat Shock Protein 90 Inhibition in Cancer Drug Discovery: From Chemistry to Futural Clinical Applications.
    Özgür A; Tutar Y
    Anticancer Agents Med Chem; 2016; 16(3):280-90. PubMed ID: 26295332
    [TBL] [Abstract][Full Text] [Related]  

  • 73. C-terminal modulators of heat shock protein of 90 kDa (HSP90): State of development and modes of action.
    Bickel D; Gohlke H
    Bioorg Med Chem; 2019 Nov; 27(21):115080. PubMed ID: 31519378
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Associations of HSP90 client proteins in human breast cancer.
    Shipp C; Watson K; Jones GL
    Anticancer Res; 2011 Jun; 31(6):2095-101. PubMed ID: 21737627
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Therapeutic and diagnostic implications of Hsp90 activation.
    Kamal A; Boehm MF; Burrows FJ
    Trends Mol Med; 2004 Jun; 10(6):283-90. PubMed ID: 15177193
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Hydrating for resistance to radicicol.
    Duerfeldt AS; Blagg BS
    ACS Chem Biol; 2009 Apr; 4(4):245-7. PubMed ID: 19371133
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cancer: the rules of attraction.
    Neckers L; Lee YS
    Nature; 2003 Sep; 425(6956):357-9. PubMed ID: 14508471
    [No Abstract]   [Full Text] [Related]  

  • 78. Potent cytotoxic C-11 modified geldanamycin analogues.
    Tian ZQ; Wang Z; MacMillan KS; Zhou Y; Carreras CW; Mueller T; Myles DC; Liu Y
    J Med Chem; 2009 May; 52(10):3265-73. PubMed ID: 19405528
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Tanespimycin: the opportunities and challenges of targeting heat shock protein 90.
    Erlichman C
    Expert Opin Investig Drugs; 2009 Jun; 18(6):861-8. PubMed ID: 19466875
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Synthetic ansamycins prepared by a ring-expanding Claisen rearrangement. Synthesis and biological evaluation of ring and conformational analogues of the Hsp90 molecular chaperone inhibitor geldanamycin.
    McErlean CS; Proisy N; Davis CJ; Boland NA; Sharp SY; Boxall K; Slawin AM; Workman P; Moody CJ
    Org Biomol Chem; 2007 Feb; 5(3):531-46. PubMed ID: 17252137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.